MRNA · 8-K · 20260731PR000147

Liquidity and Cash Position

Moderna, Inc. · 2026-07-31 · Importance 61 · Surprise 32 · No source text

Cash, cash equivalents and investments totaled $6.9 billion at June 30, 2026, down from $7.5 billion at March 31, 2026. Six-month net cash used in operating activities was $1.156 billion, compared with $1.956 billion in the prior-year period. Cash and cash equivalents were $1.723 billion, while current and non-current investments totaled $5.187 billion at June 30, 2026. Moderna projects year-end 2026 cash and investments of $4.7 billion to $5.2 billion and had $0.9 billion remaining under its credit facility.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
cashpositiveprobable—Year-end cash and investments for 2026 are now projected to be $4.7 to $5.2 billion, an improvement of approximately $0.2 billion.
cashnegativerealized—Cash, cash equivalents and investments decreased from $7.5 billion as of March 31, 2026 to $6.9 billion as of June 30, 2026.
net_incomenegativerealized—GAAP net loss for the second quarter of 2026 was $(0.8) billion (net loss $(782) million).
liabilitynegativerealized—Accrued liabilities increased to $1,909 million as of June 30, 2026 from $1,386 million at December 31, 2025.
cashpositiverealized—Cash, cash equivalents and investments as of June 30, 2026 were $6.9 billion.
liabilitynegativerealized—Long-term debt as of June 30, 2026 was $591 million.
assetspositiverealized—Total assets as of June 30, 2026 were $10,961 million and total stockholders’ equity was $6,761 million.
cashnegativerealized—Net cash used in operating activities for the six months ended June 30, 2026 was $(1,156) million.